ULTOMIRIS / GMG

 The long-acting complement inhibitor ULTOMIRIS (ravulizumab-cwvz) was approved in the Spring of 2002 by the FDA to treat most adults with generalized myasthenia gravis (gMG). With an accelerated timeline, I co-lead multiple creative teams to develop and launch separate creative campaigns for HCP, DTC and Global simultaneously.